Acurx Pharmaceuticals Beheer
Beheer criteriumcontroles 1/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Dave Luci
Algemeen directeur
US$1.0m
Totale compensatie
| Percentage CEO-salaris | 46.4% |
| Dienstverband CEO | 6.8yrs |
| Eigendom CEO | 6.8% |
| Management gemiddelde ambtstermijn | geen gegevens |
| Gemiddelde ambtstermijn bestuur | 3.3yrs |
Recente managementupdates
Recent updates
Acurx Pharmaceuticals (NASDAQ:ACXP) Will Have To Spend Its Cash Wisely
Aug 11
Acurx Sell-Off Presents Opportunity Before Upcoming Data Release
Jan 22Here's Why We're Not Too Worried About Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation
Oct 30Is Acurx Pharmaceuticals (NASDAQ:ACXP) In A Good Position To Invest In Growth?
Jul 15Is Acurx Pharmaceuticals (NASDAQ:ACXP) In A Good Position To Deliver On Growth Plans?
Mar 04Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation
Nov 16Acurx, Pharmaceuticals drops 8.8%, announces $4.25M direct offering
Jul 25Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation
May 13Here's Why We're Not Too Worried About Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation
Jan 22Companies Like Acurx Pharmaceuticals (NASDAQ:ACXP) Can Afford To Invest In Growth
Sep 30New Antibiotics Needed For Drug-Resistant Infections, Acurx Pharmaceuticals May Have The Answers
Aug 27Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$16m |
| Jun 30 2024 | n/a | n/a | -US$17m |
| Mar 31 2024 | n/a | n/a | -US$16m |
| Dec 31 2023 | US$1m | US$475k | -US$15m |
| Sep 30 2023 | n/a | n/a | -US$13m |
| Jun 30 2023 | n/a | n/a | -US$13m |
| Mar 31 2023 | n/a | n/a | -US$12m |
| Dec 31 2022 | US$655k | US$475k | -US$12m |
| Sep 30 2022 | n/a | n/a | -US$11m |
| Jun 30 2022 | n/a | n/a | -US$13m |
| Mar 31 2022 | n/a | n/a | -US$14m |
| Dec 31 2021 | US$4m | US$364k | -US$13m |
| Sep 30 2021 | n/a | n/a | -US$11m |
| Jun 30 2021 | n/a | n/a | -US$8m |
| Mar 31 2021 | n/a | n/a | -US$5m |
| Dec 31 2020 | US$596k | US$277k | -US$5m |
| Dec 31 2019 | US$290k | US$267k | -US$6m |
Compensatie versus markt: De totale vergoeding ($USD 1.02M ) Dave } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 647.72K ).
Compensatie versus inkomsten: De vergoeding van Dave is gestegen terwijl het bedrijf verliesgevend is.
CEO
Dave Luci (57 yo)
6.8yrs
Tenure
US$1,023,878
Compensatie
Mr. David P. Luci, also known as Dave, CPA, J.D. Esq. served as Chairman of the Board at AMERI Holdings, Inc. since August 16, 2018 until December 12, 2018.Mr. Luci is the Co-Founder of Acurx Pharmaceutic...
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 6.8yrs | US$1.06m | 5.94% $ 1.1m | |
| Co-Founder | 6.8yrs | US$1.02m | 6.76% $ 1.3m | |
| Independent Director | 3.3yrs | US$78.94k | 0.019% $ 3.6k | |
| Independent Director | 3.3yrs | US$73.94k | 0.0095% $ 1.8k | |
| Independent Director | 3.3yrs | US$76.44k | 0.077% $ 14.8k | |
| Independent Director | 6.1yrs | US$66.44k | 0.72% $ 139.4k | |
| Independent Director & Scientific Advisor | 3.3yrs | US$61.44k | 0.11% $ 21.0k | |
| Scientific Advisor | no data | geen gegevens | geen gegevens | |
| Scientific Advisor | no data | geen gegevens | geen gegevens | |
| Scientific Advisor | no data | geen gegevens | geen gegevens | |
| Scientific Advisor | no data | geen gegevens | geen gegevens | |
| Scientific Advisor | no data | geen gegevens | geen gegevens |
3.3yrs
Gemiddelde duur
71yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van ACXP wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).